1. Home
  2. IBRX vs KRYS Comparison

IBRX vs KRYS Comparison

Compare IBRX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.94

Market Cap

7.5B

Sector

Health Care

ML Signal

HOLD

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$292.93

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
KRYS
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
7.8B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
IBRX
KRYS
Price
$7.94
$292.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
11
Target Price
$12.57
$297.60
AVG Volume (30 Days)
10.9M
281.7K
Earning Date
05-08-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
38.71
128.00
EPS
N/A
1.83
Revenue
$113,288,000.00
$389,130,000.00
Revenue This Year
$88.59
$38.74
Revenue Next Year
$131.15
$32.53
P/E Ratio
N/A
$167.97
Revenue Growth
668.31
33.94
52 Week Low
$1.95
$123.03
52 Week High
$12.43
$319.48

Technical Indicators

Market Signals
Indicator
IBRX
KRYS
Relative Strength Index (RSI) 52.20 54.63
Support Level $7.77 $244.43
Resistance Level $8.51 $293.60
Average True Range (ATR) 0.53 13.47
MACD 0.04 1.36
Stochastic Oscillator 62.50 61.18

Price Performance

Historical Comparison
IBRX
KRYS

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Share on Social Networks: